Skip to content

Chronic obstructive pulmonary disease — overview

TL;DR — COPD is persistent airflow obstruction with respiratory symptoms caused by heterogeneous airway/alveolar injury. Post-bronchodilator spirometry is required because symptoms and exposure history alone both miss and overcall disease (Ho 2019, PMID 30838057). An estimated 391.9 million adults aged 30–79 had COPD in 2019 (Adeloye 2022, PMID 35279265). Long-acting bronchodilators, pulmonary rehabilitation and smoking cessation are core; ICS is added mainly for exacerbation-prone/type-2 phenotypes and brings pneumonia risk (Wedzicha 2016, PMID 27181606; Zhang 2020, PMID 32643439). Oxygen improves survival in severe chronic resting hypoxemia but not routine moderate desaturation, and selected emphysema/hypercapnia phenotypes benefit from valves or home NIV (NOTT 1980, PMID 6776858; Albert 2016, PMID 27783918; Murphy 2017, PMID 28528348).

Definition and diagnostic anchors

  • COPD combines chronic respiratory symptoms with persistent airflow obstruction, conventionally post-bronchodilator FEV1/FVC <0.70, after considering age and clinical context (Christenson 2022, PMID 35533707).
  • Symptoms include exertional dyspnea, cough, sputum, wheeze and recurrent lower-respiratory events; symptom burden can be high despite modest FEV1 reduction and vice versa.
  • Asthma, bronchiectasis, heart failure, interstitial disease, obesity/deconditioning and upper-airway disease are important alternatives or coexisting conditions.
  • Underdiagnosis follows absent spirometry; overdiagnosis follows labeling symptomatic smokers without confirmed obstruction (Ho 2019, PMID 30838057).
  • Exacerbation is an acute worsening of dyspnea/cough/sputum requiring additional treatment; mimics include pneumonia, pulmonary embolism, heart failure and pneumothorax.

Epidemiology and burden

A 2019 modeling analysis estimated 391.9 million cases among adults aged 30–79 using the fixed-ratio definition, with prevalence 10.3%; estimates differed by smoking exposure, urbanization and region (Adeloye 2022, PMID 35279265).

GBD analysis shows chronic respiratory disease remains a major cause of death and disability, with COPD the largest component and tobacco the dominant attributable risk globally (GBD 2019 Chronic Respiratory Diseases Collaborators 2023, PMID 37229504).

Never-smoker COPD is substantial, associated with household biomass, ambient pollution, occupational dust/fume, prior infection, abnormal lung development and asthma; it may show less emphysema and different comorbidity (Yang 2022, PMID 35427530).

Mechanism sketch

Toxic exposures and susceptibility produce epithelial injury, mucus dysfunction, small-airway fibrosis/obliteration, protease–antiprotease imbalance, oxidative stress and alveolar destruction. Neutrophils, macrophages and lymphocytes participate; corticosteroid responsiveness is lower than in type-2 asthma for many patients (Barnes 2016, PMID 27373322).

COPD is not one pathway. Airway-predominant disease, emphysema, chronic bronchitis, frequent exacerbations, eosinophilic inflammation and pulmonary vascular phenotypes overlap. CT/MRI can quantify emphysema, air trapping, airway wall and vascular changes but is not a replacement for spirometry (Elbehairy 2024, PMID 38548292).

Alpha-1 antitrypsin deficiency is the best-established monogenic risk and merits testing according to respiratory-society guidance, especially because family detection and specific therapy may follow (Miravitlles 2017, PMID 29191952). COPDGene established a large imaging/genetic cohort to map broader susceptibility and phenotypes (Regan 2010, PMID 20214461).

Treatment landscape

Risk reduction and rehabilitation

Smoking cessation is the highest-yield disease-modifying intervention. The Lung Health Study's randomized cessation intervention reduced 14.5-year mortality (Anthonisen 2005, PMID 15710956).

Pulmonary rehabilitation improves dyspnea, health-related quality of life and exercise capacity; post-exacerbation timing and uptake require attention (McCarthy 2015, PMID 25705944). Vaccination, inhaler technique, physical activity, nutrition and comorbidity care are core.

Inhaled therapy

Long-acting bronchodilators reduce symptoms and exacerbations. FLAME found LABA/LAMA indacaterol–glycopyrronium superior to LABA/ICS salmeterol–fluticasone for exacerbation prevention in the enrolled population (Wedzicha 2016, PMID 27181606).

IMPACT found single-inhaler triple therapy reduced moderate/severe exacerbations versus dual therapies in symptomatic exacerbation-prone COPD but increased pneumonia versus LABA/LAMA (Lipson 2018, PMID 29668352). ETHOS likewise showed fewer exacerbations with budesonide/glycopyrrolate/formoterol than dual comparators at the higher steroid dose (Rabe 2020, PMID 32579807).

ICS pneumonia risk is dose- and molecule-sensitive in meta-analysis (Zhang 2020, PMID 32643439). Blood eosinophils help estimate likely exacerbation-prevention benefit, but are continuous and context-dependent, not a binary disease label.

Azithromycin reduced exacerbations in selected high-risk patients over one year, with hearing, resistance and QT concerns (Albert 2011, PMID 21864166). Roflumilast is an oral PDE4 inhibitor for chronic-bronchitis/frequent-exacerbation phenotypes, limited by gastrointestinal and weight/psychiatric adverse effects (Izquierdo 2010, PMID 21225021).

Oxygen and ventilation

The Nocturnal Oxygen Therapy Trial established survival benefit from continuous oxygen versus nocturnal oxygen in severe chronic hypoxemia (NOTT 1980, PMID 6776858). LOTT found no mortality/hospitalization benefit from routine long-term oxygen in stable COPD with moderate resting or exercise desaturation (Albert 2016, PMID 27783918).

After a life-threatening exacerbation with persistent hypercapnia, home NIV plus oxygen prolonged time to readmission or death versus oxygen alone in HOT-HMV (Murphy 2017, PMID 28528348).

Emphysema procedures and biologics

Endobronchial Zephyr valves improved lung function, dyspnea and quality of life in selected heterogeneous emphysema with little/no collateral ventilation, with pneumothorax risk (Criner 2018, PMID 29787288).

Dupilumab reduced exacerbations and improved lung function in COPD with blood eosinophils ≥300/µL and chronic bronchitis despite triple therapy, establishing proof of type-2 targeted treatment in a selected COPD endotype (Bhatt 2023, PMID 37272521).

Outcomes and frontier

FEV1 is important but insufficient. Exacerbations, dyspnea, exercise, health status and survival should all be measured; COPD trial patient-reported outcomes remain inconsistently selected (Afroz 2020, PMID 32801678). Contemporary mortality review emphasizes respiratory, cardiovascular and cancer causes (Halpin 2024, PMID 39078244).

Frontiers include pre-COPD/early-life trajectories, CT-defined treatable traits, biologics beyond eosinophilic disease, regeneration, and equitable access to spirometry/rehabilitation.

Quantitative landmarks that define the field

Domain Quantitative result What it changes
Population prevalence BOLD obtained post-bronchodilator spirometry in 9,425 adults across 12 sites; GOLD stage II+ prevalence was 10.1% overall, 11.8% in men and 8.5% in women (Buist 2007, PMID 17765523). COPD is not a niche consequence of heavy smoking in high-income settings.
Life course Among adults with FEV1 <80% predicted before age 40, 26% developed COPD over 22 years versus 7% with preserved early-adult FEV1; approximately half of incident COPD followed a low-attained-function rather than rapid-decline path (Lange 2015, PMID 26154786). Prevention must include lung growth and early-life determinants, not only adult decline.
Small airways Explanted GOLD 4 lungs had 72–89% fewer terminal bronchioles and 81–99.7% less terminal-bronchiole cross-sectional area than controls; loss preceded emphysematous destruction (McDonough 2011, PMID 22029978). Conventional spirometry is a late integrator of earlier structural injury.
Systemic biology In ECLIPSE, 16% had persistent systemic inflammation; mortality was 13% versus 2% and exacerbations 1.5 versus 0.9/year compared with the non-inflamed group, without proof of causality (Agustí 2012, PMID 22624038). “Inflammatory COPD” is heterogeneous and longitudinal, not a universal state.
Maintenance bronchodilation UPLIFT maintained pre-bronchodilator FEV1 advantages of 87–103 mL over four years but did not change the post-day-30 rate of FEV1 decline (Tashkin 2008, PMID 18836213). Symptom/event benefit and disease-modification claims must be separated.
Steroid withdrawal In WISDOM, stepwise ICS withdrawal was non-inferior for first moderate/severe exacerbation (HR 1.06, 95% CI 0.94–1.19) but reduced trough FEV1 by 43 mL at week 52 (Magnussen 2014, PMID 25196117). Average safety does not eliminate subgroup-specific loss of control.
Acute steroids Five versus 14 days of prednisone produced a 180-day re-exacerbation difference of −1.2 percentage points (95% CI −12.2 to 9.8) while halving mean cumulative dose (Leuppi 2013, PMID 23695200). Shorter systemic-steroid exposure can preserve event control.
Rehabilitation delivery Minimal-resource home PR was equivalent to centre PR at program end for 6-minute walk distance (between-group difference 18.6 m, 95% CI −3.3 to 40.7), but neither model maintained gains at 12 months (Holland 2017, PMID 27672116). Access and maintenance are separate implementation problems.
Hypercapnic respiratory failure CO2-targeted long-term NIV reduced 1-year mortality from 33% to 12% in stable severe hypercapnic COPD (HR 0.24, 95% CI 0.11–0.49) (Köhnlein 2014, PMID 25066329). NIV efficacy depends on phenotype and an effective physiological target.
Precision biologics MATINEE reduced moderate/severe exacerbations from 1.01 to 0.80/year in eosinophilic COPD (rate ratio 0.79, 95% CI 0.66–0.94) without significant symptom or quality-of-life differences (Sciurba 2025, PMID 40305712). Replication of a pathway signal does not imply uniform multidomain benefit.

Central controversies

  • A fixed FEV1/FVC ratio is simple and prognostically useful, but can label healthy older never-smokers as obstructed; LLN reduced apparent obstruction in one elderly reference population, while prospective outcome validation remains incomplete (Wang 2013, PMID 24034095).
  • Pharmacotherapy improves symptoms and events, yet UPLIFT did not alter long-term FEV1 decline, reinforcing a distinction between control and structural disease modification (Tashkin 2008, PMID 18836213).
  • COPD can arise through accelerated decline or low maximally attained lung function; the former trajectory carried higher all-cause mortality in one long-term cohort (HR 1.93, 95% CI 1.14–3.26), so identical late spirometry need not imply identical biology or prognosis (Marott 2020, PMID 32289231).
  • Type-2 treatment is no longer a simple positive/negative story: benralizumab phase 3 primary comparisons were neutral, whereas dupilumab and later mepolizumab succeeded in differently selected populations (Criner 2019, PMID 31112385; Sciurba 2025, PMID 40305712).

Evidence breadth: mortality is not a single treatment endpoint

Three evidence streams prevent an overly treatment-centric reading of survival. In TORCH adjudication, 911 deaths were 35% respiratory, 27% cardiovascular and 21% cancer; site investigators and the blinded endpoint committee agreed on primary cause only 52% of the time (McGarvey 2007, PMID 17311843). In SUMMIT, 16,485 people with moderate COPD and cardiovascular risk had no significant mortality benefit from fluticasone furoate/vilanterol (HR 0.88, 95% CI 0.74–1.04) and no cardiovascular-composite benefit (HR 0.93, 0.75–1.14), despite an 8 mL/year (1–15) slowing of FEV1 decline (Vestbo 2016, PMID 27203508). Conversely, a six-trial meta-analysis found lower mortality for one-year single-inhaler triple therapy versus LABA/LAMA (RR 0.69, 95% CI 0.53–0.90), but not versus ICS/LABA (RR 0.94, 0.72–1.24), alongside more pneumonia than LABA/LAMA (RR 1.43, 1.21–1.68) (Lai 2022, PMID 35207460). The contradiction is clinically useful: cause adjudication, comparator choice, prior ICS exposure and population enrichment determine what “mortality benefit” can mean.

The broader causal frame also widens the intervention horizon. A Lancet Commission argues that exposure control across the life course, earlier biological detection and etiotype-based classification are required because spirometric COPD is a late, heterogeneous endpoint (Stolz 2022, PMID 36075255). In 8,352 participants followed from age seven to 53, the childhood profile combining frequent asthma, bronchitis and allergy predicted 261 mL lower FEV1, 3.4 percentage-points lower FEV1/FVC and COPD OR 4.9 (95% CI 2.1–11.0); adult asthma mediated 62.5% and lower childhood lung function 26.5% of the association (Bui 2018, PMID 29894209). COPD prevention therefore begins before adult tobacco exposure, without diminishing tobacco control.

Detection is an intervention only when care changes

Community symptom screening followed by spirometry identified undiagnosed asthma or COPD in 595 of 38,353 interviewees; among 508 randomized participants, pulmonologist/educator-led guideline care reduced participant-initiated respiratory health-care use from 1.12 to 0.53 events/person-year (incidence-rate ratio 0.48, 95% CI 0.36–0.63), improved FEV1 by 94 mL (95% CI 50–138) relative to usual care, and produced smaller between-group gains in SGRQ (−3.5 points, 95% CI −6.0 to −0.9) and CAT (−1.3, 95% CI −2.4 to −0.1) (Aaron 2024, PMID 38767248). The mixed asthma/COPD population and specialist-led treatment package mean this is evidence for a case-finding-to-treatment pathway, not for untargeted COPD screening or spirometry alone.

A Czech position paper organizes stable COPD around clinical phenotypes and treatable traits rather than a single escalating drug ladder, illustrating how national guidance can accept the same diagnostic construct yet operationalize heterogeneity differently (Zatloukal 2020, PMID 33325455). Whether such phenotype systems improve outcomes over simpler exacerbation/eosinophil algorithms remains unresolved.

Open questions

  • Can pre-COPD be identified early without medicalizing normal variation? (Christenson 2022, PMID 35533707)
  • Which eosinophilic patients need ICS, dupilumab or both? (Lipson 2018, PMID 29668352; Bhatt 2023, PMID 37272521)
  • Can imaging phenotypes predict treatment rather than merely describe anatomy? (Elbehairy 2024, PMID 38548292)
  • How should long-term oxygen be targeted between severe and moderate hypoxemia? (NOTT 1980, PMID 6776858; Albert 2016, PMID 27783918)
  • Which systems close global spirometry and rehabilitation gaps? (Ho 2019, PMID 30838057; McCarthy 2015, PMID 25705944)

References

  1. Christenson SA, et al. Chronic obstructive pulmonary disease. Lancet. 2022. PMID 35533707
  2. Adeloye D, et al. Global prevalence and risk factors for COPD in 2019. Lancet Respir Med. 2022. PMID 35279265
  3. GBD 2019 Chronic Respiratory Diseases Collaborators. Global chronic-respiratory-disease burden. EClinicalMedicine. 2023. PMID 37229504
  4. Ho T, et al. Under- and over-diagnosis of COPD. Breathe (Sheff). 2019. PMID 30838057
  5. Yang IA, et al. COPD in never-smokers. Lancet Respir Med. 2022. PMID 35427530
  6. Barnes PJ. Inflammatory mechanisms in COPD. J Allergy Clin Immunol. 2016. PMID 27373322
  7. Elbehairy AF, et al. Advances in COPD imaging using CT and MRI: linkage with lung physiology and clinical outcomes. Eur Respir J. 2024. PMID 38548292
  8. Miravitlles M, et al. ERS statement on alpha-1 antitrypsin deficiency. Eur Respir J. 2017. PMID 29191952
  9. Regan EA, et al. COPDGene study design. COPD. 2010. PMID 20214461
  10. Anthonisen NR, et al. Smoking-cessation intervention and 14.5-year mortality. Ann Intern Med. 2005. PMID 15710956
  11. McCarthy B, et al. Pulmonary rehabilitation for COPD. Cochrane Database Syst Rev. 2015. PMID 25705944
  12. Wedzicha JA, et al. FLAME: indacaterol–glycopyrronium versus salmeterol–fluticasone. N Engl J Med. 2016. PMID 27181606
  13. Lipson DA, et al. IMPACT single-inhaler triple therapy. N Engl J Med. 2018. PMID 29668352
  14. Rabe KF, et al. ETHOS triple therapy at two steroid doses. N Engl J Med. 2020. PMID 32579807
  15. Zhang Q, et al. Pneumonia risk with different inhaled corticosteroids in COPD patients: a meta-analysis. COPD. 2020. PMID 32643439
  16. Albert RK, et al. Azithromycin for prevention of COPD exacerbations. N Engl J Med. 2011. PMID 21864166
  17. Izquierdo JL, et al. Roflumilast for COPD. Drugs Today (Barc). 2010. PMID 21225021
  18. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen in hypoxemic COPD. Ann Intern Med. 1980. PMID 6776858
  19. Albert RK, et al. Long-term oxygen for COPD with moderate desaturation. N Engl J Med. 2016. PMID 27783918
  20. Murphy PB, et al. Home NIV plus oxygen after hypercapnic exacerbation. JAMA. 2017. PMID 28528348
  21. Criner GJ, et al. LIBERATE Zephyr endobronchial-valve trial. Am J Respir Crit Care Med. 2018. PMID 29787288
  22. Bhatt SP, et al. Dupilumab for eosinophilic COPD. N Engl J Med. 2023. PMID 37272521
  23. Afroz N, et al. Patient-reported outcomes in COPD trials. Int J Chron Obstruct Pulmon Dis. 2020. PMID 32801678
  24. Halpin DMG. Mortality of patients with COPD. Expert Rev Respir Med. 2024. PMID 39078244
  25. Buist AS, et al. International variation in the prevalence of COPD (the BOLD Study). Lancet. 2007. PMID 17765523
  26. Lange P, et al. Lung-function trajectories leading to COPD. N Engl J Med. 2015. PMID 26154786
  27. McDonough JE, et al. Small-airway obstruction and emphysema in COPD. N Engl J Med. 2011. PMID 22029978
  28. Agustí A, et al. Persistent systemic inflammation and poor clinical outcomes in COPD. PLoS One. 2012. PMID 22624038
  29. Tashkin DP, et al. A 4-year trial of tiotropium in COPD. N Engl J Med. 2008. PMID 18836213
  30. Magnussen H, et al. Withdrawal of inhaled glucocorticoids and COPD exacerbations. N Engl J Med. 2014. PMID 25196117
  31. Leuppi JD, et al. Short-term versus conventional glucocorticoid therapy in acute COPD exacerbations. JAMA. 2013. PMID 23695200
  32. Holland AE, et al. Home-based rehabilitation for COPD using minimal resources. Thorax. 2017. PMID 27672116
  33. Köhnlein T, et al. Non-invasive positive-pressure ventilation for severe stable COPD. Lancet Respir Med. 2014. PMID 25066329
  34. Sciurba FC, et al. Mepolizumab to prevent exacerbations of eosinophilic COPD. N Engl J Med. 2025. PMID 40305712
  35. Wang Y, et al. Lower limit of normal and airflow-limitation misclassification. Chin Med J (Engl). 2013. PMID 24034095
  36. Marott JL, et al. Lung-function trajectories as predictors of exacerbations and mortality. Am J Respir Crit Care Med. 2020. PMID 32289231
  37. Criner GJ, et al. Benralizumab for prevention of COPD exacerbations. N Engl J Med. 2019. PMID 31112385
  38. McGarvey LP, et al. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax. 2007. PMID 17311843
  39. Vestbo J, et al. Fluticasone furoate and vilanterol and survival in COPD with heightened cardiovascular risk (SUMMIT). Lancet. 2016. PMID 27203508
  40. Lai CC, et al. Impact of 52-week single-inhaler triple versus dual therapy on mortality in COPD: systematic review and meta-analysis. Life (Basel). 2022. PMID 35207460
  41. Stolz D, et al. Towards the elimination of COPD: a Lancet Commission. Lancet. 2022. PMID 36075255
  42. Bui DS, et al. Childhood respiratory risk-factor profiles and middle-age lung function. Ann Am Thorac Soc. 2018. PMID 29894209
  43. Aaron SD, et al. Early diagnosis and treatment of COPD and asthma: a randomized, controlled trial. N Engl J Med. 2024. PMID 38767248
  44. Zatloukal J, et al. Chronic obstructive pulmonary disease—diagnosis and management of stable disease; a personalized approach using treatable traits. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020. PMID 33325455